Major NMSG multicenter studies - ongoing: active including or follow-up

NMSG 23#15
A prospective phase 2 study to assess the minimal residual disease after ixazomib plus lenalidomide and dexamethasone (IRd) treatment for newly diagnosed transplant eligible myeloma patients
pdfSynopsis

NMSG 20#13
A phase II study of carfilzomib-cyclophosphamide-dexamethasone and high-dose melphalan followed by randomization between observation or maintenance with carfil-zomib and dexamethasone in patients with relapsed multiple myeloma after high-dose melphalan with autologous stem cell support
pdfSynopsis

NMSG 22#14 The Magnolia Study
Prolonged Protection from Bone Disease in Multiple Myeloma. An open label phase 4 multicenter international randomised trial
pdfSynopsis

HOVON 126 - NMSG 21#13
Ixazomib citrate-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib citrate or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; a randomized phase II trial
pdfSynopsis

EMN12 - HOVON 129 PCL
Carfilzomib and lenalidomide-based treatment for younger and elderly newly diagnosed primary plasma cell leukemia patients
pdfSynopsis

HOVON 87 – NMSG 18
Randomized phase III trial in elderly patients with previously untreated symptomatic Multiple Myeloma comparing MP-Thalidomide (MP-Thal) followed by thalidomide maintenance versus MP-Lenalidomide (MP-Len) followed by maintenance with lenalidomide
pdfSynopsis

EMN02 - HOVON 95 MM
A randomized phase III study to compare Bortezomib, Melphalan, Prednisone (VMP) with High Dose Melphalan followed by Bortezomib, Lenalidomide, Dexamethasone (VRD) consolidation and Lenalidomide maintenance in patients with newly diagnosed multiple 
pdfSynopsis

Nordic MRD substudy in EMN-02; about 40 patients in CR with sequential BMF

 

Major NMSG multicenter studies - former and finalized studies

MP-T + Thal maintenance vs. MP-R + Rev maintenance as first line treatment in elderly newly diagnosed (phase III, NMSG-HOVON-study; interim at ASH 2014)

NOP in refractory myeloma (phase II) and newly diagnosed myeloma (phase III)

MP vs. MP+IFNa (phase III)          

High-dose chemotherapy + stem cell support in patients < 60 years (vs. historical control)

High-dose chemotherapy + stem cell support in patients < 65 years (vs. historical control)

Induction chemotherapy VAD vs. Cy-Dex (phase III)

Induction chemotherapy Cy-Fludarabin-Dex vs. Cy-Dex (phase II)

MP vs. MP-T in elderly newly diagnosed (phase III)

Pamidronate 90 mg vs. 30 mg in bone protection (phase III)

Bortezomib-Dex vs. Thalidomide-Dex in first relapse (phase III)

Bortezomib consolidation vs. no consolidation post-ASCT (phase III)

Bortezomib-Dex re-induction  followed by Bortezomib+Melfalan conditioning and ASCT in first relaps after prior ASCT (phase II)

Login